Business & Tech
MedImmune Strikes Deal Worth Up to $500 Million
MedImmune would mesh with another Gaithersburg-based firm in a deal expected to support cancer research.
In a deal worth up to $500 million, MedImmune will acquire Amplimmune, a private firm that was a Johns Hopkins University spinoff, the Washington Business Journal reports.
The move is expected to bolster cancer-related research, MedImmune’s parent company AstraZeneca said in a news release Monday. Amplimmune launched in 2007 as a Johns Hopkins “spinout” that focused on immune-based biologics, The Business Journal reports.
MedImmune and Amplimmune are based in Gaithersburg.
Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.
According to AstraZeneca, MedImmune would initially pay $225 million and could possibly pay another $275 million if certain “development milestones” were reached.
The deal is expected to close later this year.
Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
We’ve removed the ability to reply as we work to make improvements. Learn more here
